Francesco Giorgino

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik, Francesco Giorgino, Esteban Jódar et al. · The Lancet · 2021 · 560 citations

Once-daily Insulin Degludec, Metabolic Syndrome, Diabetes Management +11

Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects.

Laurie J. Goodyear, Francesco Giorgino, L. Sherman et al. · Journal of Clinical Investigation · 1995 · 524 citations · Full text

Insulin Receptor Phosphorylation, Insulin Receptor, Insulin Signaling +21

Feasibility and effectiveness of a disease and care management model in the primary health care system for patients with heart failure and diabetes (Project Leonardo)

Marco Matteo Ciccone, Francesco Bux, Francesca Cortese et al. · Vascular Health and Risk Management · 2010 · 307 citations · Full text

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Olga Vaccaro, Maria Masulli, Antonio Nicolucci et al. · The Lancet Diabetes & Endocrinology · 2017 · 285 citations

Diabetes Management, Cardiovascular Disease, Diabetes +9